sparsentan
sparsentan: sourced relationships with 1 company · 9 clinical trials tracked.
sparsentan evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
How could sparsentan → TVTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| Travere Therapeutics, Inc. (TVTX) Immunoglobulin A Nephropathy; Focal Segmental Glomeruloscler… | Phase 4 |
| Travere Therapeutics, Inc. (TVTX) Focal segmental glomerulosclerosis (FSGS) | BLA Filed |
| Travere Therapeutics, Inc. (TVTX) Reduction of proteinuria in adults with primary IgA nephropa… | Approved |
Clinical Trial Registry Records (9)
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Primary endpoint: Change in urine to protein creatinine ratio (UPCR)
A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)
Primary endpoint: Urinary protein/creatinine ratio (UPCR)
A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With Immunoglobulin A Nephropathy (IgAN)
Primary endpoint: Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24
Effects of Simultaneous ETA & AT1 Receptor Antagonism on Endothelial Function & Vascular Stiffness in ANCA-associated Vasculitis (SPARsentan in VASCulitis - SPARVASC)
Primary endpoint: Forearm blood flow
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of interest (AEOIs)
A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A Nephropathy
Primary endpoint: Urine protein/creatinine ratio (UP/C) at Week 36
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
Primary endpoint: Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Primary endpoint: Slope of Estimated Glomerular Filtration Rate (eGFR)
Efficacy and Safety of Sparsentan (RE-021), a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Primary endpoint: Percent Change in Urine Protein/Creatinine (Up/C)
Frequently asked questions
Which companies have sourced relationships with sparsentan?
sparsentan has dated SEC/FDA relationship records for Travere Therapeutics, Inc..
How many clinical trials involve sparsentan?
BioSniper tracks 9 clinical trials involving sparsentan.